From Trials to Triumph—Glenmark Launches Game-Changing Immunotherapy

Unknown Apr 02, 2026 1,550 Views

Glenmark Pharmaceuticals Ltd (NSE: GLEN.NS) has rolled out Tevimbra (tislelizumab) in India, which is a significant addition to the oncology portfolio of the company. Tevimbra is an immune checkpoint inhibitor of PD-1 that is intended to treat cancer like NSCLC and ESCC. The roll-out is in line w...